Arsenal Capital Partners Appoints Spaight As Operating Partner

Oct 17 2016 | 7:07pm ET

Close on the heels of raising $1.3 billion for its latest private equity fund, Arsenal Capital Partners has brought former WIL Research Company CEO David Spaight aboard as an operating partner within the firm’s healthcare group.

Spaight led the successful turnaround of WIL Research, a global contract research organization focused on preclinical R&D and contract development and manufacturing services, and led the firm’s $585 million sale to Charles River Laboratories earlier this year. Prior to joining WIL Research in 2010, Spaight held senior executive positions at leading biopharma services and life sciences companies including MDS Pharma Services, ThermoFisher and PerkinElmer. 

“David’s career has been characterized by 30 years of innovative executive leadership experience in biopharma services and life sciences,” said Dr. Donald Deieso, Arsenal operating partner and co-head of Arsenal’s healthcare group, in a statement. “We are delighted to have him bring his unique set of skills to help guide the growth and impact of our portfolio companies.”

Founded in 2000 and based in New York, Arsenal Capital Partners invests in lower middle-market specialty industrial and healthcare companies. Since inception, Arsenal has raised institutional equity investment funds totaling $2.975 billion, has made 34 platform investments and completed 21 realizations since inception.

In Depth

Caliber: Making the Most Out of Marketing and Public Relations

Oct 5 2016 | 7:09pm ET

It has never been harder for small to medium-sized alternative investment firms...


U.S. Trust's Beard: The Rapid Growth of the Art Lending Industry

Oct 7 2016 | 10:55pm ET

Alternative investment managers have emerged as some of the most significant art...

Guest Contributor

Hedge Fund Marketing – Tips for Your Initial Sales Meeting

Sep 29 2016 | 5:46pm ET

There are two main goals a hedge fund should have for an initial in-person sales...